A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
150
Intravitreal injection
Sham injections
Mean change in BCVA
Mean change in BCVA from Day 1 to the average of Week 20 and Week 24.
Time frame: Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Network Arizona
Scottsdale, Arizona, United States
NOT_YET_RECRUITINGGlobal Research Management, Inc.
Glendale, California, United States
NOT_YET_RECRUITINGUCLA Stein Eye Institute
Los Angeles, California, United States
NOT_YET_RECRUITINGStanford Byers Eye Institute
Palo Alto, California, United States
NOT_YET_RECRUITINGCalifornia Eye Specialists Medical Group, Inc.
Pasadena, California, United States
RECRUITINGCalifornia Eye Specialists Medical Group, Inc.
Redlands, California, United States
NOT_YET_RECRUITINGRetina Consultants of Southern California
Redlands, California, United States
NOT_YET_RECRUITINGRetinal Consultants Medical Group Inc
Sacramento, California, United States
RECRUITINGRetina Group of New England, PC
Waterford, Connecticut, United States
RECRUITINGRetina Group of Florida (Ft. Lauderdale)
Fort Lauderdale, Florida, United States
NOT_YET_RECRUITING...and 23 more locations